News NICE wants to axe funding for two thyroid cancer drugs NICE unconvinced by survival data from Ipsen and Sanofi drugs
News FDA approves Pfizer's Besponsa in aggressive blood cancer Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.
News AZ and Merck & Co ovarian cancer drug gets expanded US use FDA approves Lynparza's use in a wider group of women.
News BMS shares fall after latest Opdivo disappointment BMS waiting for overall survival data of Opdivo and Yervoy in kidney cancer
News Biofrontera mulls US IPO to fund skin cancer drug German biotech Biofrontera is considering a US stock market listing to fund development and marketing of a skin cancer drug.
Views & Analysis Evolving immunotherapy strategies in NSCLC Status of immunotherapies in non-small cell lung cancer (NSCLC).
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
